Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) – Research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Spyre Therapeutics in a research report issued on Tuesday, April 8th. Leerink Partnrs analyst F. Khurshid anticipates that the company will post earnings per share of ($0.83) for the quarter. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Spyre Therapeutics’ current full-year earnings is ($4.46) per share. Leerink Partnrs also issued estimates for Spyre Therapeutics’ Q2 2025 earnings at ($0.83) EPS, Q3 2025 earnings at ($0.84) EPS, Q4 2025 earnings at ($0.85) EPS, FY2025 earnings at ($3.35) EPS and FY2026 earnings at ($3.18) EPS.
Other equities research analysts have also recently issued research reports about the company. Leerink Partners started coverage on Spyre Therapeutics in a report on Tuesday. They issued an “outperform” rating and a $45.00 price target for the company. Wolfe Research assumed coverage on Spyre Therapeutics in a research note on Tuesday, March 18th. They issued an “outperform” rating and a $27.00 target price for the company. Wedbush reissued an “outperform” rating and set a $65.00 price target on shares of Spyre Therapeutics in a research report on Monday, January 13th. Finally, The Goldman Sachs Group upgraded shares of Spyre Therapeutics to a “strong-buy” rating in a research report on Tuesday, February 18th. Eight analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $49.57.
Spyre Therapeutics Trading Down 10.8 %
SYRE stock opened at $11.93 on Thursday. The company has a market cap of $718.87 million, a price-to-earnings ratio of -1.60 and a beta of 3.05. The firm has a 50-day moving average of $18.69 and a two-hundred day moving average of $24.40. Spyre Therapeutics has a 12 month low of $10.91 and a 12 month high of $40.84.
Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($0.89) by $0.08.
Institutional Trading of Spyre Therapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Spyre Therapeutics by 4.2% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,741 shares of the company’s stock worth $527,000 after buying an additional 916 shares during the period. GF Fund Management CO. LTD. purchased a new position in shares of Spyre Therapeutics during the 4th quarter worth approximately $29,000. MetLife Investment Management LLC boosted its position in shares of Spyre Therapeutics by 6.2% during the 4th quarter. MetLife Investment Management LLC now owns 21,382 shares of the company’s stock worth $498,000 after purchasing an additional 1,250 shares during the period. Huntington National Bank acquired a new stake in Spyre Therapeutics in the 4th quarter valued at approximately $34,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in Spyre Therapeutics in the fourth quarter valued at approximately $46,000. 80.39% of the stock is owned by institutional investors and hedge funds.
Spyre Therapeutics Company Profile
Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).
Featured Articles
- Five stocks we like better than Spyre Therapeutics
- Investing In Preferred Stock vs. Common Stock
- Joby Aviation: Operational Momentum vs. Market Sentiment
- What Are Trending Stocks? Trending Stocks Explained
- Broadcom’s Big Outperformance Shows Strength Amid Tariff Decline
- How to trade using analyst ratings
- Carvana: Can Turnaround Strength Outdrive Market Headwinds?
Receive News & Ratings for Spyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.